BIAF bioAffinity Technologies, Inc.
Healthcare$1.65+5.77%ClosedMarket Cap: $7.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.92
P/S
1.25
EV/EBITDA
-0.35
DCF Value
$-281.43
FCF Yield
-153.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
22.1%
Operating Margin
-204.3%
Net Margin
-280.6%
ROE
-358.8%
ROA
-199.9%
ROIC
-229.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.4M | 22.8% | $-3.6M | $-3.6M | $— | — |
| Q4 null | $1.6M | 18.9% | $-3.1M | $-3.1M | $— | — |
| FY null | $6.2M | 23.2% | $-10.6M | $-14.9M | $— | — |
| Q3 null | $1.4M | 27.0% | $-2.3M | $-5.1M | $— | — |
| Q2 null | $1.3M | 19.9% | $-2.5M | $-4.1M | $— | — |
| Q1 null | $1.9M | 26.2% | $-2.6M | $-2.7M | $— | — |
| Q4 null | $2.2M | 22.3% | $-2.9M | $-3.0M | $— | — |
| FY null | $9.4M | 36.1% | $-9.0M | $-9.0M | $— | — |
| Q3 null | $2.4M | 38.7% | $-2.0M | $-2.0M | $— | — |
| Q2 null | $2.4M | 41.3% | $-2.1M | $-2.1M | $— | — |
| Q1 null | $2.4M | 34.6% | $-1.9M | $-2.0M | $— | — |
| Q4 2023 | $2.2M | 18.1% | $-2.3M | $-2.4M | $-7.80 | — |